July - September 2021, Volume 17, Issue 3

Dima V

Actualities in Neonatal Endocrine and Metabolic Screening

Acta Endo (Buc) 2021, 17 (3): 394-399
doi: 10.4183/aeb.2021.394

Neonatal metabolic screening has proven to be an important tool for the early detection of innate metabolic errors. Despite the fact that simple and effective methods of testing for metabolic diseases have been identified since the middle of the twentieth century, no consensus has been reached so far on the content of neonatal metabolic screening panels. There are large differences between countries in the number of metabolic diseases identified through national metabolic screening programs, ranging from zero to several tens, the most common testing being for phenylketonuria and congenital hypothyroidism (including in Romania). Given the fact that rare but treatable diseases have been identified in recent decades, reducing the financial burden on the health system, it would be useful to include them in the national neonatal metabolic screening program.

Keywords: neonatal metabolic screening, innate metabolic errors, costs, consensus, expansion.

Correspondence: Vlad Dima MD, “Filantropia” Clinical Hospital of Obstetrics and Gynecology, 11-13 Ion Mihalache Blvd., Bucharest, 011171, Romania, E-mail: dima.vlad@yahoo.com